ABSTRACT
PURPOSE: To characterize the nanoparticle of antroquinonol from A. cinnamomea and its ameliorative effects on the reproductive dysfunction in the diabetic male rat. MATERIAL AND METHODS: The chitosan-silicate nanoparticle was used as the carrier for the delivery of antroquinonol from solid-state-cultured A. cinnamomea extract (AC). The rats were fed with a high-fat diet and intraperitoneally injected with streptozotocin to induce diabetes. The rats were daily oral gavage by water [Diabetes (DM) and Control groups], three different doses of chitosan-silicate nanoparticle of antroquinonol from solid-state-cultured A. cinnamomea (nano-SAC, NAC): (DM+NAC1x, 4 mg/kg of body weight; DM+NAC2x, 8 mg/kg; and DM+NAC5x, 20 mg/kg), solid-state-cultured AC (DM+AC5x, 20 mg/kg), or metformin (DM+Met, 200 mg/kg) for 7 weeks. RESULTS: The nano-SAC size was 37.68±5.91 nm, the zeta potential was 4.13±0.49 mV, encapsulation efficiency was 79.29±0.77%, and loading capacity was 32.45±0.02%. The nano-SAC can improve diabetes-induced reproductive dysfunction by regulating glucose, insulin, and oxidative enzyme and by increasing the level of testosterone, follicle-stimulating hormone, luteinizing hormone, and sperm count as well as sperm mobility. In testicular histopathology, the seminiferous tubules of A. cinnamomea-supplemented diabetic rats showed similar morphology with the control group. CONCLUSION: The nanoparticle of antroquinonol from Antrodia cinnamomea can be used as an effective strategy to improve diabetes-induced testicular dysfunction.
Subject(s)
Antrodia/chemistry , Diabetes Mellitus, Experimental/drug therapy , Nanoparticles/chemistry , Reproduction , Ubiquinone/analogs & derivatives , Animals , Blood Glucose/metabolism , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Disease Models, Animal , Fasting/blood , Glutathione Peroxidase/metabolism , Humans , Insulin/adverse effects , Insulin/blood , Kidney/drug effects , Kidney/physiopathology , Liver/drug effects , Liver/physiopathology , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Rats, Sprague-Dawley , Sperm Count , Sperm Motility/drug effects , Streptozocin , Superoxide Dismutase/metabolism , Testis/drug effects , Testis/pathology , Ubiquinone/pharmacology , Ubiquinone/therapeutic useABSTRACT
Patient-derived organoids (PDOs) are emerging as preclinical models with promising values in personalized cancer therapy. The purpose of this study was to establish a living biobank of PDOs from patients with non-small cell lung cancer (NSCLC) and to study the responses of PDOs to drugs. PDOs derived from NSCLC were cultured in vitro, and then treated with natural compounds including chelerythrine chloride, cantharidin, harmine, berberine and betaine with series of concentrations (0.5-30 µM) for drug screening. Phenotypic features and treatment responses of established PDOs were reported. Cell lines (H1299, H460 and H1650) were used for drug screening. We successfully established a living NSCLC organoids biobank of 10 patients, which showed similar pathological features with primary tumors. Nine of the 10 patients showed mutations in EGFR. Natural compounds chelerythrine chloride, cantharidin and harmine showed anticancer activity on PDOs and cell lines. There was no significant difference in the 95% confidence interval (CI) for the IC50 value of chelerythrine chloride between PDOs (1.56-2.88 µM) and cell lines (1.45-3.73 µM, p>0.05). PDOs were sensitive to berberine (95% CI, 0.092-1.55 µM), whereas cell lines showed a resistance (95% CI, 46.57-2275 µM, p<0.0001). PDOs had a higher IC50 value of cantharidin, and a lower IC50 value of harmine than cell lines (p<0.05, 7.50-10.45 µM and 4.27-6.50 µM in PDOs, 3.07-4.44 µM and 4.69-544.99 µM in cell lines, respectively). Both PDOs and cell lines were resistant to betaine. Chelerythrine chloride showed the highest inhibitory effect in both models. Our study established a living biobank of PDOs from NSCLC patients, which might be used for high-throughput drug screening and for promising personalized therapy design.
Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Non-Small-Cell Lung , Drug Evaluation, Preclinical , Lung Neoplasms , Organoids/drug effects , Cell Line, Tumor , HumansABSTRACT
Amorphous silica is increasingly used in diagnostic and biomedical research because of its ease of production and relatively low cost. It is generally regarded as safe and has been approved for use as a food or animal feed ingredient. Recent literature reveals that amorphous silica may present toxicity concerns at high doses. In anticipation of potential human exposure to silica, it is advisable to examine its toxicity to cells of different organs. Consequently, we investigated the response of several normal fibroblast and tumor cells to varying doses of amorphous silica or composite nanoparticles of silica and chitosan. A cell proliferation assay indicates that silica nanoparticles are nontoxic at low dosages but that cell viability decreases at high dosages. A lactate dehydrogenase (LDH) assay indicates that high dosages of silica induce cell membrane damage. Both assays reveal that fibroblast cells with long doubling times are more susceptible to injury induced by silica exposure than tumor cells with short doubling times. In contrast, silica-chitosan composite nanoparticles induce less inhibition in cell proliferation and less membrane damage. This study suggests that the cytotoxicity of silica to human cells depends strongly on their metabolic activities but that it could be significantly reduced by synthesizing silica with chitosan.
Subject(s)
Cell Division/drug effects , Nanoparticles/toxicity , Silicon Dioxide/toxicity , Cell Division/physiology , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Proliferation/drug effects , Chitosan , Humans , L-Lactate Dehydrogenase/metabolism , Microscopy, Electron, Scanning , Spectrum AnalysisABSTRACT
The purpose is to investigate the cervical spinal cord mapping on electrical stimulation at LI4 (Hegu) by using 'signal enhancement by extravascular water protons' (SEEP)-fMRI, and to establish the response of acupoint-stimulation in spinal cord. Three healthy volunteers were underwent low-frequency electrical stimulation at LI4. Meanwhile, a single-shot fast spin-echo (SSFSE) sequence was used to perform functional MR imaging on a 1.5 T GE Signa MR system. Cord activation was measured both in the sagittal and transverse imaging planes and then analyzed by AFNI (analysis of functional neuroimages) system. In the sagittal view, two subjects had an fMRI response in the cervical spinal cord upon electrical stimulation at LI4. The localizations of the segmental fMRI activation are both at C6 through T1 and C2/3 cervical spinal cord level. In the transverse imaging plane, significant fMRI responses could be measured in the last subjects locating at C6/7 segment, the cross-sectional localization of the activity measured in the spinal cord was most in terms of the ipsilateral posterior direction. It is concluded that the fMRI technique can be used for detecting with activity in the human cervical spinal cord by a single-shot fast spin-echo sequence on a 1.5 T GE clinical system. Investigating the acupoint-stimulation response in the spinal cord using the spinal fMRI will be helpful for the further discussion on the mechanisms of acupuncture to spinal cord diseases.
Subject(s)
Action Potentials/physiology , Electric Stimulation/methods , Electroacupuncture/methods , Evoked Potentials/physiology , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Spinal Cord/physiology , Adult , Cervical Vertebrae/physiology , Humans , MaleABSTRACT
The objective of the research project was to investigate whether fenofibrate treatment may alter the biochemical content of the oxidized LDL and consequently its ability to impair the endothelium-dependent relaxation in hyperlipidemic patients. We hypothesized that fenofibrate treatment of hyperlipidemic patients may attenuate the ability of their oxidized LDL to impair the endothelium-dependent relaxation of the blood vessels as a consequence of fenofibrate-induced changes to the content and composition of lysoPC in the LDL molecule. Hyperlipidemic patients (Type IIb and Type IV) were recruited from the Lipid Clinic, HSC, Winnipeg, Canada, for this study. A blood sample was taken immediately after the recruitment, a second sample was taken after 6 weeks of dietary treatment, and a third sample was taken after 8 weeks of fenofibrate treatment. LDL was isolated from the plasma and oxidized by copper sulfate. Fenofibrate was shown to be highly effect in the reduction of total cholesterol, LDL cholesterol and triglycerides in these patients. Fenofibrate treatment also caused the attenuation of impairment of endothelium-dependent relaxation by the oxidized LDL from these patients. A slight reduction of lysophosphatidylcholine level was also found in the oxidized LDL of the fenofibrate treated patients, relative to LDL isolated after dietary treatment. In addition there were no changes in the fatty acid levels of the lysophosphatidylcholine isolated from LDL. Taken together, our results suggest that while the reduced lysophosphatidylcholine levels may contribute to the attenuated impairment of the endothelium-dependent relaxation of the aortic ring, other unidentified factors impacted by fenofibrate are likely to contribute to the attenuated effects.
Subject(s)
Endothelium, Vascular/physiology , Fenofibrate/therapeutic use , Hyperlipidemias/drug therapy , Hypolipidemic Agents/therapeutic use , Lipoproteins, LDL/blood , Muscle, Smooth, Vascular/physiology , Vasodilation/physiology , Acetylcholine/metabolism , Animals , Aorta, Thoracic , Cholesterol/blood , Cholesterol, LDL/blood , Chromatography, Gas/methods , Humans , Hyperlipidemias/metabolism , Lipids/analysis , Lipids/blood , Lysophosphatidylcholines/metabolism , Oxidation-Reduction , Rats , Triglycerides/bloodABSTRACT
Female C57BL/6 mice infected with the LP-BM5 leukaemia retrovirus developed murine acquired immune-deficiency syndrome (AIDS). Dehydroepiandrosterone (DHEA) and melatonin (MLT) modify immune dysfunction and prevent lipid peroxidation. We investigated whether DHEA and MLT could prevent immune dysfunction, excessive lipid peroxidation, and tissue vitamin E loss induced by retrovirus infection. Retrovirus infection inhibited the release of T helper 1 (Th1) cytokines, stimulated secretion of Th2 cytokines, increased hepatic lipid peroxidation, and induced vitamin E deficiency. Treatment with DHEA or MLT alone, as well as together, largely prevented the reduction of B- and T-cell proliferation as well as of Th1 cytokine secretion caused by retrovirus infection. Supplementation also suppressed the elevated production of Th2 cytokines stimulated by retrovirus infection. DHEA and MLT simultaneously reduced hepatic lipid peroxidation and prevented vitamin E loss. The use of DHEA plus MLT was more effective in preventing retrovirus-induced immune dysfunction than either DHEA or MLT alone. These results suggest that supplementation with DHEA and MLT may prevent cytokine dysregulation, lipid oxidation and tissue vitamin E loss induced by retrovirus infection. Similarly, hormone supplementation also modified immune function and increased tissue vitamin E levels in uninfected mice.
Subject(s)
Antioxidants/therapeutic use , Dehydroepiandrosterone/therapeutic use , Melatonin/therapeutic use , Murine Acquired Immunodeficiency Syndrome/virology , Retroviridae Infections/immunology , Vitamin E/metabolism , Animals , B-Lymphocytes/pathology , Cell Division/drug effects , Cholesterol/analysis , Cholesterol/metabolism , Cytokines/metabolism , Drug Therapy, Combination , Female , Lipid Peroxidation , Liver/chemistry , Liver/metabolism , Mice , Mice, Inbred C57BL , Murine Acquired Immunodeficiency Syndrome/drug therapy , Murine Acquired Immunodeficiency Syndrome/immunology , Phospholipids/analysis , Phospholipids/metabolism , Retroviridae Infections/drug therapy , T-Lymphocytes/pathology , Th1 Cells/metabolism , Th2 Cells/metabolism , Vitamin E/analysisABSTRACT
OBJECTIVE: To study the clinical effect of Taozhi Zhipu Mixture (TZM) in preventing postoperative intestinal adhesion. METHODS: Three hundred and ninety-six patients who had received abdominal operation were randomly divided into the treated group (188 cases) and the control group (208 cases). Same treatment was given to both groups excepting that the treated group received TZM orally or by nasogastric tube. The time of borborygmus recovering and first passing of flatus-defecation after operation was recorded. Patient's gastro-intestinal motion was observed by isotope tracing with I131 capsule. The frequency and intensity of borborygmus were measured by a tracer. All patients had been followed up for 2-3 years. RESULTS: The recovery of borborygmus, the first passing of flatus-defecation were much earlier, the I131 capsule passed gastro-intestinal tract more quickly, and tracer showed higher frequency and intensity of borborygmus in the treated group than those in the control group. Follow-up study also showed the treated group was better than the control group in the non-adhesion rate and the total effective rate (P < 0.05). CONCLUSION: TZM has good effect on stimulating postoperational gastro-intestinal peristalsis and preventing the occurrence of postoperational intestinal adhesion.
Subject(s)
Appendicitis/surgery , Drugs, Chinese Herbal/therapeutic use , Intestinal Diseases/prevention & control , Intestinal Obstruction/surgery , Adolescent , Adult , Aged , Appendectomy/adverse effects , Female , Humans , Intestinal Diseases/etiology , Male , Middle Aged , Tissue Adhesions/etiology , Tissue Adhesions/prevention & controlABSTRACT
Previous studies showed EWE could strongly inhibit the proliferation of tumor cells in vivo. Experimental results also showed that EWE had antitumor effect in S180-bearing mice and H22-bearing mice and prolonged life-span in S180-bearing mice in this paper, Furthermore, it was found that EWE could improve the immune function of S180-bearing mice. Therefore EWE can be considered as a potent antitumor herb.
Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Drugs, Chinese Herbal/therapeutic use , Euphorbia/chemistry , Phytotherapy , Plants, Medicinal/chemistry , Sarcoma 180/drug therapy , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/pharmacology , Liver Neoplasms, Experimental/drug therapy , Liver Neoplasms, Experimental/pathology , Mice , Neoplasm Transplantation , Organ Size , Plant Roots/chemistry , Sarcoma 180/immunology , Sarcoma 180/pathology , Survival Rate , Thymus Gland/pathology , Tumor Cells, CulturedABSTRACT
Antitumor activity of the aquatic extract the root of Euphorbia helioscopia L (EWE) in Vitro were studied. Viable cells count, MTT staining and colonal formation assays of three kinds of cancer cells were used to assess the antitumor activity. Determined by viable cells count, the IC50 values of EWE against 7721, Hela, MKN-45 cells were 1.26, 1.98, 1.72 mg/ml respectively (72 h). Determined MTT staining, the IC50 values EWE against 7721, Hela, MKN-45 cells were 1.43, 1.67, 0.97 mg/ml. Determined by colonal formation, the inhibition rate of EWE (4 mg/ml) against 7721, Hela, MKN-45 cells were 59.8%, 66.4%, 70.5%. The results indicated that EWE had obvious antitumor activity.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Drugs, Chinese Herbal/pharmacology , Euphorbia , Plants, Medicinal , Cell Division/drug effects , Drugs, Chinese Herbal/isolation & purification , Euphorbia/chemistry , HeLa Cells/drug effects , Humans , Inhibitory Concentration 50 , Liver Neoplasms/pathology , Plant Roots/chemistry , Plants, Medicinal/chemistry , Stomach Neoplasms/pathology , Tumor Cells, Cultured/drug effectsABSTRACT
Most malignant gliomas recur locally, despite the fact that these tumors are usually found to be diffusely infiltrating on pathologic studies. Thus, efforts have concentrated on local disease control as an initial step to improve the prognosis of these patients. This review discusses the most recent studies on locoregional approaches in therapy for this poor-prognosis neoplasm. Emphasis is placed on the radiotherapeutic and combined modality (radiotherapy and chemotherapy) approaches reported during the past year.
Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Glioma/radiotherapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Boron Neutron Capture Therapy , Brachytherapy , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Chemotherapy, Adjuvant , Clinical Trials as Topic , Combined Modality Therapy , Cranial Irradiation , Glioma/drug therapy , Glioma/mortality , Glioma/pathology , Glioma/surgery , Humans , Hyperbaric Oxygenation , Neoplasm Recurrence, Local/radiotherapy , Radiation-Sensitizing Agents/therapeutic use , Radioisotope Teletherapy , Radiotherapy, Adjuvant , Remission Induction , Treatment OutcomeABSTRACT
Tissue levels of the antioxidants melatonin (MLT) and dehydroepiandrosterone (DHEA) decline with age, and this decline is correlated with immune dysfunction. The aim of the current study is to determine whether hormone supplementation with MLT and DHEA together would synergize to reverse immune senescence. Old (16.5 months) female C57BL/6 mice were treated with DHEA, MLT, or DHEA + MLT. As expected, splenocytes were significantly (P < 0.05) higher in old mice as compared to young mice. DHEA, MLT, and DHEA + MLT significantly (P < 0.005) increased B cell proliferation in young mice. However, only MLT and DHEA + MLT significantly (P < 0.05) increased B cell proliferation in old mice. DHEA, MLT, and DHEA + MLT help to regulate immune function in aged female C57BL/6 mice by significantly (P < 0.05) increasing Th1 cytokines, IL-2, and IFN-gamma or significantly (P < 0.05) decreasing Th2 cytokines, IL-6, and IL-10, thus regulating cytokine production. DHEA and MLT effectively modulate suppressed Th1 cytokine and elevated Th2 cytokine production; however, their combined use produced only a limited additive effect.
Subject(s)
Antioxidants/pharmacology , Cytokines/metabolism , Dehydroepiandrosterone/pharmacology , Melatonin/pharmacology , Th1 Cells/drug effects , Th2 Cells/drug effects , Animals , Cytotoxicity, Immunologic , Drug Combinations , Drug Synergism , Enzyme-Linked Immunosorbent Assay , Female , Killer Cells, Natural/immunology , Lymphocyte Subsets , Mice , Mice, Inbred C57BL , Organ Size/drug effects , Spleen/drug effects , Spleen/metabolism , Th1 Cells/metabolism , Th2 Cells/metabolism , Thymus Gland/drug effects , Thymus Gland/metabolismABSTRACT
The paper reported technological study on extracting Prunus mandshurica oils by supercritical-CO2 fluid, mainly researched the influence of pressure, temperature, time and flow rate of CO2 on the oil yield, determined optimum technology of extracting the oils, compared the oils from SFE-CO2 and traditional technology.
Subject(s)
Carbon Dioxide , Plant Extracts/isolation & purification , Plant Oils/chemistry , Plant Oils/isolation & purification , Prunus/chemistry , Chromatography, Supercritical Fluid/methods , Pressure , Seeds/chemistry , Technology, Pharmaceutical/methods , Temperature , TimeABSTRACT
Ageing, leukaemia and acquired immune deficiency syndrome (AIDS) are conditions with dysregulated cytokine production. As dehydroepiandrosterone sulphate (DHEAS) restored normal cytokine production in old mice its effects on retrovirally infected old mice were investigated. Retrovirus infection and ageing-induced immune dysfunction. Murine retrovirus-infected old C57BL/6 female mice consumed 0.22 or 0.44 microgram of DHEAS/mouse/day beginning 2 weeks postinfection for 10 weeks. DHEAS largely prevented the retrovirus-induced reduction in T-cell and B-cell mitogenesis. DHEAS supplement prevented loss of cytokines [interleukin-2 (IL-2) and interferon-gamma] secretion by mitogen-stimulated splenocytes representing T helper 1 (Th1) cell phenotypes. It also suppressed the retrovirus-induced, excessive production of cytokines (IL-6 and IL-10) by Th2 cells. The highest dose of DHEAS reduced IL-6 production by splenocytes from uninfected old mice by 75% while increasing their IL-2 secretion by nearly 50%. Thus immune dysfunction induced by ageing, even when exacerbated by murine retrovirus infection, was largely prevented by DHEAS.
Subject(s)
Aging/immunology , Dehydroepiandrosterone Sulfate/therapeutic use , Murine Acquired Immunodeficiency Syndrome/drug therapy , Murine Acquired Immunodeficiency Syndrome/immunology , Animals , Body Weight/drug effects , Cell Division/drug effects , Cytokines/biosynthesis , Female , Mice , Mice, Inbred C57BL , Spleen/immunology , Th1 Cells/immunology , Th2 Cells/immunologyABSTRACT
Female C57BL/6 mice were infected with LP-BM5 retrovirus, causing murine acquired immunodeficiency syndrome (AIDS), which is functionally similar to human AIDS. Retrovirus infection inhibited release of T-helper 1 cytokines, stimulated secretion of T-helper 2 cytokines and induced hepatic and cardiac vitamin E deficiency with increased lipid peroxides. We hypothesized that the immune dysfunction caused increased oxidation and loss of vitamin E. Because T-cell receptor (TCR) peptide treatment blocked the excessive stimulation of a T-cell subset by retroviral superantigens, we tested whether maintenance of normal immune function during infection prevented excessive oxidative damage. The TCR peptide treatments with doses > 100 microgram/mouse and administered 2-4 wk postinfection significantly inhibited the retrovirus-induced immune dysfunction, concomitantly reduced tissue oxidative damage and thereby largely maintained vitamin E concentration in the liver and heart. Reducing the dose of peptide or delaying administration until early murine AIDS had developed resulted in severe immune dysfunction that caused elevated tissue lipid peroxidation and loss of vitamin E. The TCR peptide treatment partially maintained production of interleukin-2 (IL-2) and prevented retrovirus-induced elevated production of IL-6 by splenocytes in vitro. In conclusion, TCR peptide treatment during murine retrovirus infection ameliorated immune dysfunction and thus prevented increases in tissue lipid peroxidation and vitamin E loss. T-cell immune dysfunction and its prevention by TCR peptide treatment is important in the therapy of vitamin E deficiency induced by retrovirus infection.
Subject(s)
Immune System/physiopathology , Murine Acquired Immunodeficiency Syndrome/complications , Peptide Fragments/therapeutic use , Receptors, Antigen, T-Cell/physiology , Vitamin E Deficiency/prevention & control , Adjuvants, Immunologic/pharmacology , Amino Acid Sequence , Animals , Body Weight/physiology , Female , Interleukin-2/metabolism , Interleukin-6/metabolism , Lipid Peroxidation , Liver/chemistry , Liver/metabolism , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Murine Acquired Immunodeficiency Syndrome/metabolism , Myocardium/chemistry , Myocardium/metabolism , Peptide Fragments/analysis , Random Allocation , Receptors, Antigen, T-Cell/chemistry , Vitamin E/analysis , Vitamin E/metabolism , Vitamin E Deficiency/etiology , Vitamin E Deficiency/physiopathologyABSTRACT
Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the major regulatory enzyme of the mevalonate pathway of cholesterol synthesis), displays antitumor activity in experimental models. We therefore conducted a Phase I trial to characterize the tolerability of lovastatin administered at progressively higher doses to cancer patients. From January 1992 to July 1994, 88 patients with solid tumors (median age, 57 +/- 14 years) were treated p.o. with 7-day courses of lovastatin given monthly at doses ranging from 2 to 45 mg/kg/day. The inhibitory effects of lovastatin were monitored through serum concentrations of cholesterol and ubiquinone, two end products of the mevalonate pathway. Concentrations of lovastatin and its active metabolites were also determined, by bioassay, in the serum of selected patients. Cyclical treatment with lovastatin markedly inhibited the mevalonate pathway, evidenced by reductions in both cholesterol and ubiquinone concentrations, by up to 43 and 49% of pretreatment values, respectively. The effect was transient, however, and its magnitude appeared to be dose independent. Drug concentrations reached up to 3.9 micrometer and were in the range associated with antiproliferative activity in vitro. Myopathy was the dose-limiting toxicity. Other toxicities included nausea, diarrhea, and fatigue. Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients. One minor response was documented in a patient with recurrent high-grade glioma. Lovastatin given p.o. at a dose of 25 mg/kg daily for 7 consecutive days is well tolerated. The occurrence of myopathy, the dose-limiting toxicity, can be prevented by ubiquinone supplementation. To improve on the transient inhibitory activity of this dosing regimen on the mevalonate pathway, alternative schedules based on uninterrupted administration of lovastatin should also be studied.
Subject(s)
Antineoplastic Agents/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Lovastatin/adverse effects , Neoplasms/drug therapy , Adult , Aged , Female , Humans , Lovastatin/pharmacology , Male , Middle Aged , Neoplasms/blood , Ubiquinone/bloodABSTRACT
Pycnogenol is a commercial mixture of bioflavonoids that exhibits antioxidative activity. The effects of dietary pycnogenol on immune dysfunction in normal mice as well as those fed ethanol or infected with the LP-BM5 murine retrovirus were determined. The ethanol consumption and retrovirus infection caused abnormalities in the function and/or structure of a broad array of cells involved in humoral and cellular immunity. Pycnogenol enhanced in vitro IL-2 production by mitogen-stimulated splenocytes if its production was suppressed in ethanol-fed or retrovirus-infected mice. Mitogenesis of splenocytes did not show a significant change in mice treated with pycnogenol. It reduced the elevated levels of interleukin-6 produced in vitro by cells from retrovirus infected mice and IL-10 secreted by spleen cells from mice consuming ethanol. Natural killer cell cytotoxicity was increased with pycnogenol treatment.
Subject(s)
Adjuvants, Immunologic/pharmacology , Ethanol/pharmacology , Flavonoids/pharmacology , Murine Acquired Immunodeficiency Syndrome/immunology , Alcoholism/immunology , Animals , Antibody Formation/drug effects , Cytokines/analysis , Cytokines/biosynthesis , Cytotoxicity, Immunologic/drug effects , Enzyme-Linked Immunosorbent Assay , Female , Immunity, Cellular/drug effects , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukemia, Experimental , Liver/metabolism , Lymphocyte Activation/drug effects , Mice , Mice, Inbred C57BL , Plant Extracts , Spleen/immunology , Vitamin E/metabolismABSTRACT
Murine retrovirus infection induces loss of vitamin E and immune dysfunction with loss of cytokine production by T-helper cells. Therefore interferon-gamma (IFN-gamma) was given during dietary vitamin E supplementation to effectively prevent murine retrovirus-induced immunosuppression, cytokine dysregulation, and development of murine AIDS. Administration of IFN-gamma during vitamin E supplementation significantly prevented development of retrovirus-induced suppression of splenic natural killer cell activity and T cell proliferation. It also significantly slowed retrovirus-induced elevation of T helper (Th) 2 cytokine [interleukin (IL)-4, IL-5, and IL-10] production and monokine (IL-6 and tumor necrosis factor-alpha) secretion by splenocytes. The treatment also prevented loss of Th1 cytokine (IL-2 and IFN-gamma) secretion by splenocytes from retrovirus-infected mice alleviating splenomegaly and hypergammaglobulinemia. The combined therapy had an additive therapeutic impact. It was more effective than IFN-gamma treatment or vitamin E supplementation alone in delaying the development of retrovirus-induced immunosuppression with its cytokine dysregulation.
Subject(s)
Interferon-gamma/pharmacology , Murine Acquired Immunodeficiency Syndrome/immunology , Vitamin E/pharmacology , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Cytokines/biosynthesis , Female , Immune Tolerance/drug effects , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Lymphocyte Activation/drug effects , Mice , Mice, Inbred C57BL , Vitamin E/metabolismABSTRACT
Female C57BL/6 mice were infected with LP-BM5 retrovirus, causing murine AIDS, which is functionally similar to human AIDS. Vitamin E effects on immune functions, cytokine production and nutritional concentrations in retrovirus-infected mice were determined. Retrovirus infection inhibited release of interleukin-2 (IL) and interferon-gamma (IFN) and some immune functions, whereas it stimulated secretion of IL-4, IL-5, IL-6 and tumor necrosis factor-alpha (TNF) and immunoglobulin (Ig) production. Furthermore, retrovirus infection induced some nutritional deficiencies in the tissues. A 15-fold increase in dietary vitamin E largely restored concentrations of some micronutrients (vitamins A and E, zinc and copper) in the liver, intestine, serum and thymus. It also partially restored production of IL-2 and IFN-gamma by splenocytes. Retrovirus-induced elevated production of IL-4, IL-5 and IL-6 by splenocytes in vitro was normalized by vitamin E. Elevated release of IL-6, TNF-alpha, IgA and IgG produced by splenocytes in vitro during murine AIDS were also completely or partially normalized by vitamin E. Vitamin E also prevented retrovirus-induced suppression of splenocyte proliferation and natural killer cell activity. These data indicate that vitamin E supplementation during murine AIDS can help to ameliorate the disorders during murine AIDS, suggesting vitamin E usefulness in treatment of AIDS in humans.
Subject(s)
Murine Acquired Immunodeficiency Syndrome/immunology , Nutritional Status , Vitamin E/therapeutic use , Animals , Female , Immunoglobulin A/biosynthesis , Immunoglobulin G/biosynthesis , Interferon-gamma/metabolism , Interleukin-2/metabolism , Interleukin-4/metabolism , Interleukin-5/metabolism , Interleukin-6/metabolism , Killer Cells, Natural/immunology , Liver/metabolism , Mice , Mice, Inbred C57BL , Murine Acquired Immunodeficiency Syndrome/drug therapy , Murine Acquired Immunodeficiency Syndrome/physiopathology , Spleen/cytology , Spleen/immunology , Tumor Necrosis Factor-alpha/metabolism , Vitamin E/administration & dosageABSTRACT
The new guttae ophthalmic Xiaoxingzhang (XXZ) was extracted from Radix Actinidiae, a traditional Chinese herbal drug. The 50% inhibition concentration (IC50) of XXZ on type I Herpes Simplex Virus (HSV-1) in virus cell cultures is 165.48-174.73 micrograms/ml. However, XXZ concentrations greater than 400 micrograms/ml did not cause any microscopically visible disruption of vero cells. The efficacy of XXZ in the treatment of experimental Herpes Simplex Keratitis (HSK) in rabbits is higher than that of idoxuridine. The effective doses of XXZ are not toxic to corneal epithelium. The results suggest that XXZ as a new anti-HSV preparation is potentialy useful in the treatment of patients with HSK.